Continuous Antibiotic Infusion In Children
Continuous intravenous antibiotic infusion using elastomeric pumps is well established in adult care and has been shown to be effective, safe, and cost-efficient, particularly for beta-lactams and vancomycin. In pediatric outpatient parenteral antimicrobial therapy (p-OPAT), home intravenous treatment is feasible and s
| Condition(s) | Infection |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Summary | Continuous intravenous antibiotic infusion using elastomeric pumps is well established in adult care and has been shown to be effective, safe, and cost-efficient, particularly for beta-lactams and vancomycin. In pediatric outpatient parenteral antimicrobial therapy (p-OPAT), home intravenous treatment is feasible and safe, improves quality of life, and reduces hospital stays and healthcare-associated infections. Elastomeric pumps offer practical advantages, including portability, ease of use, fixed infusion rates, and reduced drug handling, although they are limited by fixed flow rates and drug stability. This prospective study at Tampere University Hospital (Tays) will evaluate the safety and cost-effectiveness of 24-hour continuous antibiotic infusions in children between January 2026 an |
| Who can participate | Inclusion Criteria: * iv-antibiotic treatment is necessary * clinically stable * no need to stay in hospital * pump or cassette can be changed at the hospital or at home * care givers are able to contact hospital if needed * clinical diagnose is not uncertain * no allergy for the used antibiotic * the continuous antibiotic infusion hasn't been started yet or it has been initiated no more than 24 hours prior to study enrolment Exclusion Criteria: * the pump cannot be carried with the child * the child must stay at the hospital for monitoring or other reason * unclear diagnose |
| Ages | 16 Years |
| Sex | All |
| Lead sponsor | Tampere University Hospital |
| Locations | Tampere, Finland |
| Start date | 2026-04-21 |
| NCT ID | NCT07575009 |
| Official listing | https://clinicaltrials.gov/study/NCT07575009 |